VYZULTA™: A New FDA Approved Glaucoma Medication with Dual Action
On November 2, 2017, the FDA approved VYZULTA™ (latanoprostene bunod 0.024%) for the treatment of glaucoma. This newly available medication treats glaucoma in two distinct ways. One of these methods of protecting the optic nerve has already been available to those...Next-Generation Glaucoma Medications and Surgeries
Part 12 of 14 of “Adjusting the Faucet or Opening the Drain – Currently Available Methods to Treat the Plumbing Problem of Open Angle Glaucoma” | A San Gabriel Valley Optometric Society (SGVOS) Continuing Education Dinner Event – 2 hours CE | Featured...Vesneo: A New Glaucoma Medication With Dual Action
Vesneo (latanoprostene bunod) is an experimental glaucoma medication developed by French pharmaceutical firm Nicox. It is essentially a prostaglandin analog “plus”. Find out more…
Could a New Class of Glaucoma Medications Be Around The Corner?
An exciting new class of potential glaucoma medications include what are termed the ROCK and ROCK/NET inhibitors. And it’s about time! Twenty years have passed since the last new class of medications (prostaglandin analogs) were approved for the treatment of glaucoma.